On July 19, 2019, Salarius Pharmaceuticals Inc., formerly known as Flex Pharma Inc. (the “Registrant”), completed its business combination with Salarius Pharmaceuticals, LLC (“Private Salarius”) in accordance with the terms of the Agreement and Plan of Merger (as amended, the “Merger Agreement”), dated as of January 3, 2019 and amended on June 27, 2019, by and among the Registrant, Falcon Acquisition Sub, LLC (“Merger Sub”), and Private Salarius, pursuant to which Merger Sub merged with and into Private Salarius, with Private Salarius surviving as a wholly owned subsidiary of the company (the “Merger”). In accordance with the Merger Agreement, on July 19, 2019, at the effective time of the Merger, Peter Barton Hutt, Marc Kozin, Stuart Randle, Michelle Stacy and Roger Tung (together, the “Prior Directors”) resigned from the Registrant's board of directors and any respective committees of the board of directors to which they belonged. Also on July 18, 2019, the Prior Directors approved an increase to the number of directors comprising the board of directors to seven and appointed, effective as of the effective time of the Merger, David J. Arthur, Tess Burleson, Arnold C. Hanish, Paul Lammers, Bruce J. McCreedy, William K. McVicar and Jonathan P. Northrup as directors of the Registrant.

Pursuant to the Merger Agreement, on July 19, 2019, as of the effective time of the Merger, the Prior Directors resigned from the Registrant's board of directors and any respective committees of the board of directors on which they served, which resignations were not the result of any disagreements with the company relating to the Registrant's operations, policies or practices. Also, pursuant to the Merger Agreement, on July 19, 2019, as of the effective time of the Merger, each of William K. McVicar, the Registrant's president and chief executive officer, and John McCabe, the Registrant's chief financial officer and secretary, resigned as an officer of the Registrant. Effective as of the effective time of the Merger, the Registrant's board of directors appointed David J. Arthur as the Registrant's president and chief executive officer, and Scott Jordan as the Registrant's chief financial officer.

There are no family relationships among any of the Registrant's directors and executive officers. On July 19, 2019, Arnold C. Hanish, Tess Burleson and Bruce J. McCreedy were appointed to the audit committee of the Registrant's board of directors, and Mr. Hanish was appointed as the chair of the audit committee. On July 19, 2019, Bruce J. McCreedy, Arnold C. Hanish and Paul Lammers were appointed to the compensation committee of the Registrant's board of directors, and Mr. McCreedy was appointed as the chair of the compensation committee.

On July 19, 2019, Tess Burleson and Paul Lammers were appointed to the nominating and corporate governance committee of the Registrant's board of directors, and Ms. Burleson was appointed as the chair of the nominating and corporate governance committee.